Supernus Pharmaceuticals Inc (SUPN) — Cash Flow Quality Index

Latest as of June 2025: 2.60x

Supernus Pharmaceuticals Inc (SUPN) has a Cash Flow Quality Index of 2.60x as of June 2025. Operating cash flow of $58.53 Million exceeds net income of $22.50 Million, indicating high earnings quality where cash backs reported profits. Explore how well can Supernus Pharmaceuticals Inc service its debt to assess how comfortably operating cash covers total debt obligations.

Cash Flow Quality Index

2.60x
Operating CF / Net Income

Operating Cash Flow

$58.53 Million
USD

Net Income

$22.50 Million
USD

Data as of

Jun 2025
Most recent filing

Supernus Pharmaceuticals Inc Cash Flow Quality Index (2009–2024)

Historical Cash Flow Quality Index for Supernus Pharmaceuticals Inc across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash efficiency ratio of Supernus Pharmaceuticals Inc.

Annual Cash Flow Quality Index for Supernus Pharmaceuticals Inc (2009–2024)

Year-by-year earnings quality comparison for Supernus Pharmaceuticals Inc.

Year Quality Index Operating CF (USD) Net Income YoY Change
2024 2.33x $171.95 Million $73.86 Million ▼ -97.2%
2023 84.41x $111.08 Million $1.32 Million ▲ +4286.6%
2022 1.92x $116.83 Million $60.71 Million ▼ -19.1%
2021 2.38x $127.13 Million $53.42 Million ▲ +118.3%
2020 1.09x $138.40 Million $126.95 Million ▼ -13.9%
2019 1.27x $143.13 Million $113.06 Million ▲ +8.9%
2018 1.16x $128.99 Million $110.99 Million ▼ -41.9%
2017 2.00x $114.64 Million $57.28 Million ▲ +173.2%
2016 0.73x $66.81 Million $91.22 Million ▼ -68.0%
2015 2.29x $32.12 Million $14.02 Million ▲ +488.9%
2014 0.39x $7.73 Million $19.87 Million ▼ -38.9%
2009 0.64x $2.63 Million $4.14 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.